SUN-627-MS201
What it found
No result yet.
What was tested
Treatment tested
- SUN-627
What it measured
Main measures
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Time Frame: From enrollment to the end of study at 16 weeks
Safety
Other measures (1)
Markers of disease in blood and brain fluid as well as imaging to measure inflammation Time Frame: from enrollment to the end of treatment at 12 weeks
Who could take part
Progressive MS · 18 and over
Inclusion: - Aged 18-70, inclusive - Diagnosis of PPMS or non-active SPMS - No MS relapses in the past 2 years - Evidence that MS has continued to get worse over time - A level of disability that fits the study requirements - Additional inclusion criteria are outlined in the full study protocol. Exclusion: - Use of certain medications or treatments before the study, or need for these treatments during the study - Current participation in another research study - Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk - Certain serious or unstable medical conditions that could make the study unsafe - Active infection, recent infection, or a history of repeated infections - Additional exclusion criteria are outlined in the full study protocol.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
To assess safety and tolerability of SUN-627
Loading reviews and guidelines…
History
Started
Oct 2026
Finished
Apr 2027
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error